PreveCeutical Files Provisional Patent Application for its COVID-19 Formulation
Vancouver, British Columbia--(Newsfile Corp. - November 23, 2020) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce it has filed a provisional application at the Australian Patent Office on November 20, 2020, entitled "Sol-Gel Cannabinoid Formulation and Antiviral Use", application number 20200904291, with the aim of seeking protection for certain cannabinoid formulations and their use in prevention and treatment of...
2020-11-23 7:30 AM EST
PreveCeutical Provides Update on Its COVID-19 Cannabinoid Sol-Gel Program
Vancouver, British Columbia--(Newsfile Corp. - November 10, 2020) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) ("PreveCeutical"), is pleased to provide an update on its COVID-19 Cannabinoid Sol-Gel Program ("COVID-19 CBD Program") (see news release dated May 4, 2020). With the successful completion of the COVID-19 CBD Program, a sol-gel based formulation has been developed to deliver medicinal cannabis. The Company will provide further information once the final report...
2020-11-10 7:00 AM EST
PreveCeutical Receives Extension of Six Months to Hold its Annual General Meeting from the Registrar of Companies, British Columbia
Vancouver, British Columbia--(Newsfile Corp. - October 29, 2020) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces that it has been granted an extension of six months by the Registrar of Companies, to hold its Annual General Meeting ("AGM")for the year 2020 under section 182(4) of the Business Corporations Act. The six months extension is from October 29, 2020, to April 29, 2021. With the challenges related to COVID-19, the...
2020-10-29 3:38 PM EDT
PreveCeutical's Application for COVID-19 Therapy Funding Update
Vancouver, British Columbia--(Newsfile Corp. - October 9, 2020) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) ("PreveCeutical") informs that in reference to its current work to develop medical countermeasures in response to COVID-19 (News Release dated May 4, 2020), PreveCeutical has received notification from the Strategic Innovation Fund ("SIF") that its proposal, which was part of the second phase of Canada's National Medical Research Strategy in response to COVID-19,...
2020-10-09 4:15 PM EDT
Veteran Johnson & Johnson Executive Dr. Ajit Shetty Joins PreveCeutical
Vancouver, British Columbia--(Newsfile Corp. - October 1, 2020) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is very pleased to announce the appointment of Dr. Ajit Shetty as an advisor and consultant for the Company. Dr. Shetty brings his extensive pharmaceutical experience leading commercial and supply chain operations and his significant educational background to the Company. Dr. Shetty spent 36 years at Johnson & Johnson ("J&J") in...
2020-10-01 11:36 AM EDT
PreveCeutical Provides Lead Pain Management Peptides Update
Vancouver, British Columbia--(Newsfile Corp. - September 8, 2020) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to provide a further update to its non-addictive analgesic program ("Analgesic Program"). Further to the news release of September 2, 2020, the Analgesic Program consisted of an iterative approach to peptide design resulting in a number of second-generation peptide analogues optimized from the most promising...
2020-09-08 7:00 AM EDT
PreveCeutical Announces Lead Pain Management Peptides Identified for Preclinical Evaluation
Vancouver, British Columbia--(Newsfile Corp. - September 2, 2020) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to provide an update to its non-addictive analgesic program ("Analgesic Program"). The Analgesic Program started in July 2018 to discover and develop analgesic peptide-based therapeutics for moderate to severe pain and inflammation. This discovery program, which utilizes a proprietary disulfide linker technology, is...
2020-09-02 7:00 AM EDT
PreveCeutical Files an Application for a Provisional Patent for Sol-gel Cannabinoids
Vancouver, British Columbia--(Newsfile Corp. - August 31, 2020) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce it has filed a provisional application at the Australian Patent Office on August 31, 2020, entitled "Cannabinoid Formulations and Methods of Use", application number 2020903103, in order to protect sol-gel formulations containing cannabinoids for nasal delivery. The patent also covers cannabinoid...
2020-08-31 7:00 AM EDT
PreveCeutical Receives AU$1,227,902 Research & Development Tax Incentive Cash Refund
Vancouver, British Columbia--(Newsfile Corp. - August 17, 2020) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that it has received AU$1,227,902 cash rebate from the Australian Federal Government's Research and Development ("R&D") Incentive Program. The cash refund is related to expenditure on eligible Australian R&D activities conducted during the financial year ended December 31, 2019. The R&D activities were...
2020-08-17 7:00 AM EDT
PreveCeutical Announces Appointment of Director and Public Officer
Vancouver, British Columbia--(Newsfile Corp. - July 30, 2020) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce the appointment of Edward James Henderson as the Public Officer and Director of its subsidiary company, PreveCeutical (Australia) Pty Ltd. (the "Subsidiary") effective immediately. Mr. Henderson is HLB Mann Judd's Managing Partner, Business Advisory Services, Tax Consulting, Brisbane, Queensland, Australia....
2020-07-30 7:00 AM EDT
PreveCeutical Approaches Completion of Non-Addictive Analgesic Program
Vancouver, British Columbia--(Newsfile Corp. - July 21, 2020) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that the current stage of the research of its disulfide linker technology in engineering analgesic peptides derived from endogenous pharmacology program ("Analgesic Program") is soon to complete. The results are currently being compiled and analyzed. The Analgesic Program started in July 2018 to expand the...
2020-07-21 7:00 AM EDT
PreveCeutical Announces Advance in the Formulation and Biological Delivery of Therapy for Diabetes and Obesity
Vancouver, British Columbia--(Newsfile Corp. - July 15, 2020) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) ("PreveCeutical"), is pleased to announce that it has successfully demonstrated that delivery efficiency can be tailored based on vector composition in its Dual Gene Therapy Research Program. This update of PreveCeutical's Dual Gene Therapy Program, (see earlier release on January 14, 2020, and June 29, 2020), has identified a promising modified delivery vector...
2020-07-15 7:00 AM EDT
PreveCeutical Confirms Receipt of CBD For Sol-Gel
Vancouver, British Columbia--(Newsfile Corp. - July 13, 2020) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) ("PreveCeutical") is pleased to inform that the cannabis product required for its cannabinoid Sol-Gel program to address the COVID-19 pandemic (the "COVID-19 Sol-gel") (News Release dated May 4, 2020), was received by Pharmacy Australia Centre of Excellence ("PACE"), University of Queensland ("UQ") on July 8, 2020. PreveCeutical can now commence with the COVID-19...
2020-07-13 7:00 AM EDT
PreveCeutical Announces Filing of Provisional Patent Application
Vancouver, British Columbia--(Newsfile Corp. - July 8, 2020) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce it has filed a provisional application at the Australian Patent Office on July 1, 2020, entitled "Peptides and Uses Thereof", application number 2020902233, with the aim of seeking protection for certain peptides analogues of dynorphin and their use in pain management. PreveCeutical's Chief Executive Officer,...
2020-07-08 7:00 AM EDT
PreveCeutical Announces Stability Data from CBD Sol-gel Product Development Program
Vancouver, British Columbia--(Newsfile Corp. - July 6, 2020) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) ("PreveCeutical"), is pleased to announce successful results from its Cannabinoid sol-gel product development program. We have successfully conducted a three-month physico-chemical stability test on cannabinoid sol-gel formulations designed for nose-to-brain ("NTB") delivery. The physical and chemical stability of formulated cannabinoid components was characterized...
2020-07-06 7:00 AM EDT
PreveCeutical Announces Promising 3D Liver Tissue Testing of Potential Therapy for Diabetes and Obesity
Vancouver, British Columbia--(Newsfile Corp. - June 29, 2020) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) ("PreveCeutical"), is pleased to announce that it has successfully designed, screened and shortlisted a panel of smart-siRNA constructs with potent gene silencing activity (in vitro) in its Dual Gene Therapy Research Program. This further update to the Company's Dual Gene Therapy Program, (see earlier release on January 14, 2020), is an important and fundamental...
2020-06-29 7:00 AM EDT
PreveCeutical Executes Agreement for Development of CBD Sol-Gel Nasal Spray Formulation as a Potential Treatment for SARS-CoV-2 Infection
Vancouver, British Columbia--(Newsfile Corp. - June 22, 2020) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) ("PreveCeutical"), is pleased to announce that on June 18th, 2020, it has contracted UniQuest Pty Ltd. ("UniQuest") to apply the cannabinoid sol-gel ("CBD Sol-Gel") technology to develop a nasal spray formulation as a potential treatment for COVID-19 caused by SARS-CoV-2 infection. The Company is not making any express or implied claims that its product has the...
2020-06-22 12:23 PM EDT
PreveCeutical Announces Sol-Gel Chemistry Fingerprinting SOPs
Vancouver, British Columbia--(Newsfile Corp. - June 17, 2020) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) ("PreveCeutical"), is pleased to announce that it has successfully developed 'Standard Operating Procedures' ("SOPs") allowing for the chemical fingerprinting (profiling) of cannabinoids present in its extracts which can be used to formulate its proprietary Sol-gels for a variety of potential therapeutic applications. This is an important development enabling a...
2020-06-17 7:00 AM EDT
PreveCeutical Issued Statement Regarding Promotional Activity
Vancouver, British Columbia--(Newsfile Corp. - June 16, 2020) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) ("PreveCeutical") provides the following information about certain promotional activities at the request of OTC Markets. On June 15, 2020, the Company was notified by OTC Markets that recently, certain materials promoting PreveCeutical's common stock were circulated via email by a third party. Copies of the promotional emails were forwarded to PreveCeutical's CFO by...
2020-06-16 7:13 PM EDT
PreveCeutical Announces Further Successful Results from The Sol-Gel Program Final Report
Vancouver, British Columbia--(Newsfile Corp. - June 15, 2020) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) ("PreveCeutical") is pleased to announce the successful completion of its cannabinoid sol-gel program (the "Sol-gel Program") with the University of Queensland ("UQ") and UniQuest Pty Ltd. ("UniQuest). The final report confirms the successful chemical profiling of the solvent-derived cannabinoid extracts from cannabis plant species, which has provided the Company...
2020-06-15 7:00 AM EDT